Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.

TSX:TH - Post by User

Theratechnologies Inc

<< Previous

Bullboard Posts

Next >>

Post by scarlet1967on Jun 10, 2021 2:34pm

169 Views

Post# 33366186

NASH

The amount of patients suffering with the condition is sizeable enough for any approved drug to be a financial blockbuster.

7 out of 10 people living with #type2diabetes in the U.S. also have nonalcoholic fatty liver disease (NAFLD). Learn more about the relationship between #T2D & #NAFLD.

While #obesity is strongly associated with #NAFLD/NASH, people who are not overweight can also have NAFLD/#NASH. Talk to your doctor about your risk factors and your options for screening and treatment. #NASHDay

An estimated 25–30% of people worldwide ???? currently have nonalcoholic fatty liver disease (#NAFLD) & 2–6% have nonalcoholic steatohepatitis (#NASH), the most severe form of NAFLD. Researchers estimate that the prevalence of #NASH could increase by over 50% by 2030. #NASHDay

Children with #obesity are at the greatest risk for developing pediatric #NAFLD and #NASH. Other factors, such as #type2diabetes, #insulin resistance, metabolic syndrome or high #cholesterol, can increase a child’s risk. #NASHDay

https://www.poz.com/article/honor-international-nash-day-2021your-liver-will-thank

<< Previous

Bullboard Posts

Next >>

Nextech CEO provides company update on Amazon deal and more